JNCI Cancer Spectrum最新文献

{"title":"Population-based registry analysis of cervical cancer trends in Tashkent, Uzbekistan 2014-2024.","authors":"Ulugbek Khudayberdievich Mirzaev, Jasur Ravshanovich Juraev, Iroda Pulatovna Sharipova, Sarvar Temurovich Islomov, Nodira Isroilovna Tursunova, Sitora Rakhmatova, Fatima Shokir Qizi Shodieva, Mirzarakhim Mirzakhakimovich Baynazarov, Khasanjon Kobiljon Ugli Odilov, Dilbar Yuldashevna Yuldasheva, Golib Abdulloyevich Khakimov","doi":"10.1093/jncics/pkag107","DOIUrl":"10.1093/jncics/pkag107","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer remains a leading cause of morbidity and mortality among women in Uzbekistan, exceeding WHO elimination targets. Despite a school-based HPV vaccination program launched in 2019, screening coverage remains low, leading to delayed diagnoses; we examined cervical cancer trends in Tashkent (2014-2024) to evaluate the impact of the Korea Foundation for International Healthcare (KOFIH) screening project and UNFPA/UNDP HPV testing initiatives.</p><p><strong>Methods: </strong>We analyzed Tashkent City Oncoregister data for women diagnosed with invasive cervical cancer or carcinoma in situ (CIS) between 2014 and 2024 (n = 2140) after data cleaning. We calculated age-standardized incidence and mortality rates, assessed survival using Kaplan-Meier methods, and identified mortality predictors using Cox regression models.</p><p><strong>Results: </strong>The age-standardized incidence of invasive cervical cancer was 14.9 per 100 000. After KOFIH and UNFPA/UNDP implementation, CIS diagnoses increased 3.4-fold (0.2-4.7 per 100 000), while the proportion of advanced-stage (III-IV) disease declined by 43%. Five-year survival showed clear stage dependence, ranging from 91.5% for CIS to 27.8% for stage IV. Age and stage were independent predictors of mortality. Crude mortality declined from 10.2 to 1.1 per 100 000 from 2014 to 2024, and case fatality decreased from 48.6% (2014-2019) to 27.2% (2020-2024).</p><p><strong>Conclusion: </strong>Organized screening through KOFIH and UNFPA initiatives can improve early detection and reduce mortality. However, 76.6% of staged invasive cases remain advanced (II-IV), and more than 80% of women have never been screened, underscoring the need to expand screening, sustain HPV vaccination, and strengthen prevention programs in Central Asia.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13694106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149136663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating efficacy and safety profile in advanced HCC: A network meta-analysis of first-line systemic therapies.","authors":"Wei Yu Chua, Joseph J Zhao, Choong-Kun Lee, Yung-Yeh Su, Suat Ying Lee, Joycelyn Jie Xin Lee, David Wai-Meng Tai, Sze Huey Tan, Raghav Sundar, Kennedy Yao Yi Ng","doi":"10.1093/jncics/pkag084","DOIUrl":"https://doi.org/10.1093/jncics/pkag084","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma(HCC) is the sixth most common cancer and the third leading cause of cancer-related death worldwide. Our updated network meta-analysis aims to compare and rank first-line treatment regimens for advanced HCC.</p><p><strong>Methods: </strong>We searched PubMed, EMBASE, Scopus, and Cochrane from inception to May 2025 for phase III RCTs investigating first-line systemic therapies for advanced HCC. Derived hazard ratios(HRs) for each study were pooled in a random-effects NMA. The primary outcome was overall survival(OS), progression-free survival(PFS), objective response rate(ORR), and ≥ Grade 3 treatment-related adverse events(TRAE) of the assessed treatment in comparison to Sorafenib and Lenvatinib. Subgroup analysis for OS and PFS was conducted using study-level HRs. P-scores were used to rank the treatment strategies numerically.</p><p><strong>Results: </strong>Seventeen studies involving 12,727 patients were included in the final analysis. Nivolumab-Ipilimumab(HR:0.61,95%CI:0.44-0.84), Atezolizumab-Bevacizumab(HR:0.66,95%CI:0.48-0.90), Durvalumab-Tremelimuma(HR:0.76,95%CI:0.59-0.97), Sintilimab-BevSim(HR:0.57,95%CI:0.41-0.80), and Camrelizumab-Rivoceranib(HR:0.62,95%CI:0.45-0.85) had superior OS compared to Sorafenib. Only Sintilimab-BevSim(HR:0.66,95%CI:0.44-0.99) and Nivolumab-Ipilimumab(HR:0.70,95%CI:0.54-0.92) had superior OS compared to Lenvatinib. Based on p-score rankings only, Nivolumab-Ipilimumab had the highest p-score for OS, PFS, and ORR among the three FDA and EMA approved combination regimens, with similar ≥ Grade 3 TRAE compared to Sorafenib. In the subgroup analysis, Atezolizumab-Cabozantinib has the highest p-score for HBV, Atezolizumab-Bevacizumab the highest for HCV, Durvalumab-Tremelimumab for non-viral aetiology, and Pembrolizumab-Lenvatinib for AFP≥400.</p><p><strong>Conclusion: </strong>Our NMA comprehensively compares therapeutic regimens across key clinical outcomes, including OS, PFS, ORR, and ≥ Grade 3 TRAE. The heterogeneity in treatment responses across patient subgroups underscores the importance of personalized approaches in managing HCC.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies.","authors":"Stefania Morganti, Se E Kim, Qingchun Jin, Jaeyoon Cha, Jacqueline E Zeigler, Alexandra B Newman, Gregory J Kirkner, Craig Snow, Yue Zheng, Julie Vincuilla, Tonia Parker, Ryan M Buehler, Brittany L Bychkovsky, Kate E Dibble, Tal Sella, Kathryn J Ruddy, Shoshana M Rosenberg, Laura C Collins, Jeffrey Peppercorn, Lidia Schapira, Virginia F Borges, Yaileen D Guzman-Arocho, Steven E Come, Ellen Warner, Philip D Poorvu, Matteo Lambertini, Giuseppe Curigliano, Melissa E Hughes, Elizabeth A Mittendorf, Tari A King, Nancy U Lin, Judy E Garber, Nabihah Tayob, Sara M Tolaney, Ann H Partridge, Filipa Lynce","doi":"10.1093/jncics/pkag055","DOIUrl":"10.1093/jncics/pkag055","url":null,"abstract":"<p><strong>Background: </strong>Whether outcomes of germline BRCA1/2 (gBRCA1/2)-associated breast cancer differ compared with sporadic tumors is controversial. We explored the impact of gBRCA1/2 pathogenic variant (PV) status beyond established prognostic features.</p><p><strong>Methods: </strong>We conducted 2 retrospective, matched cohort studies comparing gBRCA1/2 PV carriers and noncarriers with HER2-negative, stage I-III breast cancer (Clinical Outcomes Quality Database [COQD] cohort: 185 carriers, 555 noncarriers; Young Women's Breast Cancer Study [YWS] cohort: 113 carriers, 226 noncarriers). Matching factors were age, stage, hormone receptor status, and year of diagnosis. Clinicopathological features, treatments, and survival outcomes were compared between carriers and noncarriers.</p><p><strong>Results: </strong>Most patients in COQD had stage I-II disease (87.2%), and more carriers than noncarriers had genetic testing before diagnosis (33% vs 5.6%, P < .001). In YWS, 22.7% of patients had stage III tumors, and few were tested before diagnosis (14.8% of carriers vs 1.7% of noncarriers; P < .001). Carriers in COQD received chemotherapy more often than noncarriers (81.1 vs 67.0%, P < .001), including platinum (P = .010); the proportion was similar for carriers and noncarriers in YWS. After adjusting for chemotherapy, relapse-free survival was longer in carriers than noncarriers in COQD (adjusted hazard ratio = 0.48 [95% CI = 0.26 to 0.87], P = .016), and a favorable trend was observed for other survival outcomes in both cohorts. Triple-negative tumors appeared to drive the differences.</p><p><strong>Conclusions: </strong>We observed a trend toward improved outcomes in gBRCA1/2 PV carriers compared with noncarriers. These findings suggest that carriers should not receive more aggressive treatment solely based on their germline mutation status. Prospective clinical trials in this population are warranted.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13354522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148015475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and treatment-modifying impact of immune checkpoint inhibitor-associated peripheral edema: a systematic review and meta-analysis.","authors":"Anneliese Markus, Kazuya Tsuchiya, Toshiaki Takahashi, Evelyn Elias MBBCh, Mako Koseki, Yoshito Nishimura, Nicholas C Rohs, Yu Fujiwara","doi":"10.1093/jncics/pkag058","DOIUrl":"10.1093/jncics/pkag058","url":null,"abstract":"<p><strong>Background: </strong>Immune-related adverse events disrupt immune checkpoint inhibitor therapy and impact quality of life. Peripheral edema is common among patients with cancer, however the causality of peripheral edema can be unclear in the context of multidrug regimens.</p><p><strong>Methods: </strong>PubMed/MEDLINE, Embase, and Web of Science were searched to identify phase 3 randomized controlled trials (RCTs) evaluating immune checkpoint inhibitors reporting peripheral edema incidence. The incidence of edema was calculated according to adverse event, immune checkpoint inhibitor, and treatment patterns. A random-effects meta-analysis pooled odds ratios (ORs) of edema incidence between immune checkpoint inhibitor and non-immune checkpoint inhibitor groups. A systematic review characterizing the interventions for immune-related peripheral edema was also conducted.</p><p><strong>Results: </strong>From 58 RCTs (22 590 patients), treatment-related peripheral edema (grade 1-5) occurred in 2.80% (n = 195 of 6969) of patients receiving immune checkpoint inhibitor monotherapy, 4.96% (n = 112 of 2257) of patients receiving immune checkpoint inhibitor with chemotherapy, and 8.73% (n = 205 of 2349) of patients receiving immune checkpoint inhibitor with targeted therapy. Meta-analysis showed immune checkpoint inhibitor monotherapy had lower treatment-related peripheral edema incidence compared with chemotherapy (OR = 0.45, 95% CI = 0.27 to 0.73; P = .001, I2 = 69%) with the lowest relative incidence among programmed cell death protein 1 vs chemotherapy (OR = 0.41, 95% CI = 0.23 to 0.73; P = .003) and immune checkpoint inhibitor vs taxane chemotherapy (OR = 0.32, 95% CI = 0.18 to 0.58; P < .001). A systematic review of treatment outcomes for immune-related peripheral edema among 40 patients (19 studies) revealed 82.5% (n = 33 of 40) of cases received glucocorticoid treatment, and immune checkpoint inhibitors were permanently discontinued in 35% (n = 14 of 40).</p><p><strong>Conclusions: </strong>Peripheral edema is a rare but potentially serious adverse event associated with immune checkpoint inhibitors. Immune checkpoint inhibitors likely confer less peripheral edema risk than taxane therapy. To avoid unnecessary treatment interruptions, treatment discontinuation requires careful consideration, particularly when edema develops following immune checkpoint inhibitor combination therapy.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13428319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Luteinizing hormone-releasing hormone in prostate cancer treatment: from hypothalamic discovery to clinical translation.","authors":"Samuel Benisti, Fred Saad, Guila Delouya, Daniel Taussky","doi":"10.1093/jncics/pkag075","DOIUrl":"10.1093/jncics/pkag075","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>This project elucidates the pivotal scientific discoveries that culminated in the isolation of luteinizing hormone-releasing hormone (LHRH). It details the contributions of scientists Andrew Schally and Roger Guillemin, whose competitive biochemical research led to the Nobel Prize in 1977.</p><p><strong>Materials and methods: </strong>This project entails a comprehensive review of the pivotal scientific developments that culminated in the discovery of LHRH, examined through the historical lens. The sources included peer-reviewed articles, Nobel lectures, and oral history transcripts.</p><p><strong>Results: </strong>Harris first showed the anterior pituitary's regulation by the hypothalamus in 1937, establishing the principles for Schally and Guillemin. Schally and Guillemin independently isolated TRF in 1969, requiring 160 000 porcine hypothalami for purification. Both then pursued LHRH, isolating it independently in 1971 using 240 000 porcine brains and developing advanced biochemical techniques. These methods have enabled LHRH analog synthesis for prostate cancer research. In 1971, Schally demonstrated that LHRH could suppress gonadotropin secretion. Synthetic LHRH infusion in monkeys showed LHRH's ability to desensitize pituitary gonadotropin-releasing hormone receptors. This discovery enabled the use of LHRH analog treatments for hormone-sensitive conditions. Schally conducted the first clinical trials in Mexico in 1972 and organized the first LHRH agonist study for prostate cancer, which was published in 1982.</p><p><strong>Conclusions: </strong>The discovery of LHRH represents a landmark convergence of evolving physiological concepts, rigorous biochemical innovation, and impactful clinical translation, leading to the Nobel Prize. The rivalry between Schally and Guillemin led to foundational discoveries that transformed the management of androgen-dependent malignancies.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13445975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148430412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Computational identification of salient cancer care topics and themes in oncology social work notes.","authors":"Ryzen Benson, Swetha Rajkumar, Clodagh Kenny, Michelle Zhao, Ji-Hyun Chang, Theodore Scheel, Lauren Boreta, Julian C Hong","doi":"10.1093/jncics/pkag033","DOIUrl":"10.1093/jncics/pkag033","url":null,"abstract":"<p><strong>Background: </strong>Social work notes provide a multifaceted narrative of a patient's cancer journey. Topic modeling is a computational technique that can be used to organize notes into thematic clusters and study topics in oncological social work at scale. In this study, we used the BERTopic framework to perform topic modeling of cancer social work notes and identify roles and themes frequently documented in oncological social work.</p><p><strong>Methods: </strong>We collected 106 676 social work notes from 25 341 patients diagnosed with cancer at the University of California San Francisco. Notes were split at the sentence level, and BERTopic model parameters were optimized experimentally. For each BERTopic cluster, 2 annotators independently assigned labels to 250 randomly selected sentences and keyword sets, with disagreements adjudicated by a third reviewer. Given the same sentences and keywords, 3 large language models independently labelled each cluster. Finally, human-generated and large language model-generated labels were harmonized.</p><p><strong>Results: </strong>Topic modeling of social work notes revealed 15 topics, classified into 3 distinct subthemes: (1) social worker assessments of patient psychosocial needs and service provision; (2) patient-centric factors, experiences, and the impact of cancer diagnosis on lifestyle; and (3) family and caregiver experiences when caring for someone with cancer.</p><p><strong>Conclusion: </strong>Topic modeling supplemented by large language model interpretation reveals complex psychosocial themes in patients receiving social work services during cancer care experience. We envision these methods supporting research that clusters oncological social work notes into thematic cohorts for qualitative studies on how social work care differs across patient strata and how topics are differentially distributed across cancer subtypes.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13346106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147580285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pandemic-era increases in late-stage pediatric cancer diagnoses, 2020-2022.","authors":"Todd Burus, Jason Semprini","doi":"10.1093/jncics/pkag067","DOIUrl":"10.1093/jncics/pkag067","url":null,"abstract":"<p><p>COVID-19 pandemic-related disruptions may have altered pediatric cancer detection in the United States. Using the National Childhood Cancer Registry, we compared observed incidence rates among individuals aged 0-17 years during 2020-2022 with expected rates with 95% credible intervals (CrIs) derived from pre-pandemic trends. Rates were evaluated overall and by race/ethnicity, cancer site, and stage-at-diagnosis. Among 27 996 cancers diagnosed in 2020-2022, total incidence was 17.44 per 100 000, similar to the expected rate of 17.39 (95% CrI = 16.80-17.98). Annual patterns showed an incidence reduction in 2020, followed by modestly higher-than-expected rates in 2021-2022. Pandemic-era late-stage incidence was significantly higher than expected, however (10.58 vs 10.19 per 100 000). Overall, pediatric cancer incidence during the COVID-19 pandemic matched expectations, but late-stage diagnoses increased, underscoring the need to restore timely evaluation and maintain diagnostic access during health-system disruptions.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13355589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148301747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in lung cancer survival: superior outcomes in US Veterans compared with the general population.","authors":"Nikki E Rossetti, Brendan T Heiden, Daniel B Eaton, Steven Tohmasi, Nahom Seyoum, Theodore Thomas, Martin Schoen, Whitney S Brandt, Sara Malone, Yan Yan, Ana Baumann, Su-Hsin Chang, Mayank Patel, Daniel Kreisel, Ruben Nava, Bryan Meyers, Benjamin Kozower, Varun Puri","doi":"10.1093/jncics/pkag054","DOIUrl":"10.1093/jncics/pkag054","url":null,"abstract":"<p><strong>Background: </strong>Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality in the United States, but survival outcomes are shifting with evolving therapies and screening. Recent findings suggest that survival improvements vary across health-care systems, with favorable trends observed in the Veterans Health Administration (VHA). We sought to compare NSCLC survival trends across US health systems.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of patients with NSCLC (2007-2019) using data from the VHA and the National Cancer Database (NCDB), representing the non-VHA US general population. The primary exposure was health system (VHA vs non-VHA), and the primary outcome was 3-year all-cause mortality. Multivariable Cox models estimated annual adjusted overall survival (OS), with interaction terms for health system and stage.</p><p><strong>Results: </strong>Among 1 463 996 patients (VHA n = 79 027; NCDB n = 1 38 4 969), adjusted 3-year OS increased from 24% to 51% (VHA) and from 24% to 41% (non-VHA) between 2007 and 2019. The VHA survival advantage persisted in analyses stratified by stage (all P-values <.0001) and when analyses were limited to NCDB patients with Medicare or private insurance (51% vs 42% in 2019; P < .0001).</p><p><strong>Conclusions: </strong>In this nationally representative study, 3-year OS among patients with NSCLC improved between 2007 and 2019, with larger and more rapid gains observed within the VHA compared with non-VHA settings. These findings suggest that lung cancer care delivered within an integrated, publicly funded system is associated with greater and more rapidly improving survival than care delivered across a heterogeneous mix of US health-care delivery settings represented in the NCDB.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13426908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147987400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconsidering community care referrals for Veterans with lung cancer.","authors":"Drew Moghanaki, David H Harpole, Michael J Kelley","doi":"10.1093/jncics/pkag071","DOIUrl":"10.1093/jncics/pkag071","url":null,"abstract":"","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":"10 4","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13426905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148648717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Circulating Tumor Cells in Early Breast Cancer.","authors":"","doi":"10.1093/jncics/pkag059","DOIUrl":"10.1093/jncics/pkag059","url":null,"abstract":"","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":"10 4","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13500115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}